The American Diabetes Association will lower its target recommendation for blood glucose levels for children with Type 1 diabetes, according to a statement released at the association's 74th Scientific Sessions.
Some patients with Type 2 diabetes taking drugs to lower blood sugar may experience a greater drop than is healthy for them even though their disease may not be under control, according to a new study.
An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.
Once the season starts, nobody really remembers the number of stolen bases nabbed by Gregor Blanco (13) or the number of batters who could neither put a Francisco Liriano pitch into play nor tease out a walk (33). But ask the fans how many balls their favorite player knocked out of the park through spring training, chances are they'll be able to tell you. What Lilly Diabetes and Walgreens are doing is out-of-the-park stuff, where a Walgreens pharmacist dedicated to fielding questions across all disciplines will help augment a diabetes patient's experience with a deeper look into hypoglycemia.
Self-monitoring blood glucose levels in Type 2 diabetics not on an insulin regimen may contribute little to managing the disease, according to an analysis published online last month by The Cochran Library.
The recent film “Contagion” depicts the world descending to chaos due to the spread of an extremely deadly virus. But in reality, one of the most serious epidemics doesn’t come from an infectious agent but from people’s life choices.
A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.
A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.
New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.